Avicanna Inc. (TSX:AVCN)

Market Cap	20.07M -42.2%
Revenue (ttm)	25.50M +2.4%
Net Income	-1.88M
EPS	-0.02
Shares Out	118.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	422,190
Average Volume	58,571
Open	0.1850
Previous Close	0.1800
Day's Range	0.1650 - 0.1850
52-Week Range	0.1700 - 0.3900
Beta	0.33
RSI	33.04
Earnings Date	Mar 31, 2026

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 87
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.